<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To assess prognostic roles of various KRAS oncogene mutations in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, BRAF mutation status must be controlled for because BRAF mutation is associated with poor prognosis, and almost <z:hpo ids='HP_0000001'>all</z:hpo> BRAF mutants are present among KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Taking into account experimental data supporting a greater oncogenic effect of codon 12 mutations compared with codon 13 mutations, we hypothesized that KRAS codon 12-mutated <z:e sem="disease" ids="C1527249" disease_type="Neoplastic Process" abbrv="">colorectal cancers</z:e> might behave more aggressively than KRAS <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> and codon 13 mutants </plain></SENT>
<SENT sid="2" pm="."><plain>Experimental design: Using molecular pathological epidemiology database of 1,261 rectal and <z:hpo ids='HP_0003003'>colon cancers</z:hpo>, we examined clinical outcome and <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> biomarkers of KRAS codon 12 and 13 mutations in 1,075 BRAF <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> (i.e., controlling for BRAF status) </plain></SENT>
<SENT sid="3" pm="."><plain>Cox proportional hazards model was used to compute mortality HR, adjusting for potential confounders, including stage, PIK3CA mutations, microsatellite instability, CpG island methylator phenotype, and LINE-1 methylation </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Compared with patients with KRAS <z:mp ids='MP_0002169'>wild-type</z:mp>/BRAF <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> (N = 635), those with KRAS codon 12 mutations (N = 332) experienced significantly higher <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>-specific mortality [log-rank P = 0.0001; multivariate HR, 1.30; 95% confidence interval (CI), 1.02-1.67; P = 0.037], whereas KRAS codon 13-mutated cases (N = 108) were not significantly associated with prognosis </plain></SENT>
<SENT sid="5" pm="."><plain>Among the seven most common KRAS mutations, c.35G&gt;T (p.G12V; N = 93) was associated with significantly higher <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>-specific mortality (log-rank P = 0.0007; multivariate HR, 2.00; 95% CI, 1.38-2.90, P = 0.0003) compared with KRAS <z:mp ids='MP_0002169'>wild-type</z:mp>/BRAF <z:mp ids='MP_0002169'>wild-type</z:mp> cases </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: KRAS codon 12 mutations (in particular, c.35G&gt;T), but not codon 13 mutations, are associated with inferior survival in BRAF <z:mp ids='MP_0002169'>wild-type</z:mp> <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Our data highlight the importance of accurate molecular characterization in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>